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Tachyzoites of T. gondii C-56 were collected from Swiss Webster mice.
The parasites were washed, suspended in phosphate buffered saline (PBS) and
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adjusted to 10 cells per ml. One aliquot was lysed by freeze-thawing and
the fractions were separated by differential centrifugation. The second
aliquot, representing killed vaccine,- was treated with formalin. These
vaccines were respectively mixed with Freund's incomplete adjuvant and in¬
jected intraperitoneally into separate groups of mice. Three weeks later,
B16 melanoma cellf (F-j subline) were injected intravenously into the mice.
The lungs of the mice v/ere removed 21 days after the melanoma injection and
occurrence of metastasis was determined by counting the number of nodules in
these lungs. Tumor inhibition was estimated by observing the number of
nodules in the lungs of the immunized mice relative to the number of nodules
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in the lungs of the control.
The results of this study showed that the formation of metastatic
nodules of B16 melanoma (F^ subline) can be significantly inhibited in
C57BL/6J mice by pretreatment of the mice with preparations consisting of
the killed parasite, the cell membrane or the lysed cytosol of T. gondii
C-56. The results, therefore, demonstrate that inhibition of metastatic
nodules occurs not only in the presence of live or whole parasite alone
but also in the presence of fractions prepared from the whole parasite.
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Toxoplasma gdridii is an obligate, intracellular parasite. The
majority of infections caused by Toxoplasma are latent; nevertheless, the
parasite has decided effects on the host's immune system. The parasite
appears to elicit both suppressive and stimulatory effects on the host's
immune system. Immunosuppressive effects seem to be primarily directed
toward the thymus (Huldt et al., 1973). In vitro and in vivo studies have
revealed that the indefinite persistence of T. gondii in the tissue of its
host is capable of providing a constant immunogenetic stimulus which re¬
sults in a continuous population of activated macrophages.
Infection by the parasite has been shown to provide resistance
against a wide variety of phylogenetically unrelated intracellular organisms
(mahoud et al., 1976), including bacteria (Remington and Ruskin, 1968) and
protozoa (Remington et al., 1969). The most exciting activity recently
reported is that the macrophages, obtained from J* gondii-infected mice,
interact with both allogeneic and syngeneic mouse tumors. These activated
macrophages, as they are called, have been shown to inhibit the growth of
transplantable and autochuthonous tumors (Remington et al., 1971). It was
also recently demonstrated in our laboratory that latent T. gondii infection
could protect C57BL/6J mice against metastatic B16 melanoma tumors (Seele,
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1979). In all the experiments, live or whole organisms were used.
The parasite usually has a sophisticated relationship with its
host and can remain indefinitely quiescent in the host. Nevertheless, in
situations stressful to the host, the parasite produces disease severe
enough to produce clinical symptoms. In view of the clinical hazards, the
use of the live parasite as an anti-tumor agent in humans would not be
feasible.
The objective of this study is, therefore, to make a more detailed
examination of the tumor inhibitory capability of Toxoplasma gondii in
mice. The study proposes to determine whether the factor responsible for
inhibiting metastatic melanoma tumor resides in the whole parasite or




Toxoplasma gondii was first isolated by Nicolle and Manceaux (1908)
from an African rodent, Ctenodactylus gundi. The name Toxoplasma (toxo =
arc; plasma = form) is derived from the crescent shape. Various investi¬
gators from different countries have reported their observations of Toxo¬
plasma in various species thus indicating that the organism has a wide
geographical distribution and a variety of hosts. With the use of the
dye-test technique developed by Sabin and Feldman (1948), it has been
shown that all species of mammals and birds are susceptible to infection
by Toxoplasma with the felidae as the primary and definitive host (Frenkel
et al., 1970). In the scheme of Frankel and his associates (1970), the
three known modes of transmission of Toxoplasma (congenital, carnivorism
and fecal) are linked into a life cycle. The resistant oocyst in cat feces
assures the dissemination of the parasite.
Cats can acquire infection by injesting any of the three infectious
stages of Toxoplasma: the tachyzoites (in pseudocysts), the bradyzoites
(in cysts), and the sporozoites (in oocysts). The tachyzoites or trophozoites
represent the rapidly dividing form multiplying in cells of the intermediate
host and non-intestinal epithelial cells of the definitive host. Host cells
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containing numerous tachyzoites are called clones, terminal-colonies,
groups, or pseudocysts. The bradyzoites are the slowly dividing forms
within a cyst. Bradyzoites represent the true cyst form of Toxoplasma be¬
cause they divide within a well defined parasite membrane.
Gametes are the product of gametogeny. The male gamete is called
a microgamete and the female gamete is called the macrogamete. The oocyst
is the developed zygote within a two layered wall. It differs from the
cyst form because it occurs only in the intestine of cats, the definitive
host of Toxoplasma, where it completes its life cycle.
The tachyzoite multiplies asexually by repeated endodyogeny within
the host cell; endodyogeny is a specialized form of division in which two
daughter cells are formed within the mother cell. The mother cell is de¬
stroyed during the formation of the daughter cells (Sulzer et al., 1958).
Cultivation of T. gondii
Toxoplasma can be cultivated in tissue culture of enucleated cells
(Jones, 1973); Sethi et al., 1973) or in laboratory animals such as mice,
hamsters, guinea pigs and rabbits. Mice are generally used because they are
more susceptible than the other animals, and are not naturally infected
when raised in the laboratory on conmercial dry food free of cat feces
(Dubey and Frenkel, 1974).
The tachyzoites grow in the peritoneal cavity, sometimes producing
ascites. They also grow in most of the other host tissues after intraperi-
toneal inoculation of any of the three infectious stages of T. -gondii in
mice. Virulent strains, e.g. the RH strain, usually produce illness in
mice and invariably kill them sometimes within as few as three to five days.
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Tachyzoites of the virulent strain can be aspirated from the peritoneal
cavity after three days. Avirulent strains, e.g. the C-56 strain, grow
slowly in mice and free tachyzoites of this strain are often difficult to
obtain. However, tachyzoites of avirulent strains can be obtained from
the peritoneal cavity or other organs of the mice immunosuppressed with
corticosteroids (Dubey and Frenkel, 1974). To prevent bacterial infection,
the mice are treated with chlorotetracycline in their drinking water
(Frenkel etal., 1966).
Tissue cyst or latent infection of Toxoplasma gondii can be obtained
by injecting tachyzoites, bradyzoites or oocysts into mice. To obtain cysts
or latent infection from mice inoculated with strains like C-56 or RH, it is
necessary to administer anti-Toxoplasma chemotherapy to prevent death from
acute toxoplasmosis before cysts form. Sodium sulfadiazine is effective in
controlling the acute stages of toxoplasmosis in mice. The effective dose
of sulfadiazine varies with the virulence of the Toxoplasma strain. The
administration of sodium sulfadiazine in the drinking water at a concentra¬
tion of 15 mg in 100 ml (.15 mg ml~^) from day four to 12 of infection is
effective in controlling the M-7741 and C-56 strains of Toxoplasma gondii
but will not control the RH strain. For the control of this strain, sulfa¬
diazine in a concentration of 1.25 mg ml~^ of water must be administered
from day one to 21 after infection (Remington et al., 1969).
Immunity to X- qondii
Various investigators have reported the use of live, killed or
fractions of J* gondii in successfully immunizing mice against re-infection
by T. gondii. Krahenbuhl and others (1972) showed that killed vaccine as
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well as live Toxoplasma immunized mice against re-infection with Toxoplasma.
Frenkel (1967, 1971) observed that following an acute J. qondii infection,
the parasite encysts and may remain in the host indefinitely as a latent in¬
fection. Sethi and his associates (1975) showed that immune T-lymphocytes,
immune spleen cells and immune lymph node cells obtained from Toxoplasma-
infected mice were able to induce immunity in non-immune macrophages with
which they were co-cultivated in vitro. Remington and others (1970) re¬
ported that fractions of RH Toxoplasma, containing RNA, are responsible for
delayed hypersensitivity reaction and inhibition of macrophage migration
in Toxoplasma-infected mice. Jacobs and others (1959) reported that the
hemagglutination antigen ot Toxoplasma resides in the supernatant fluid of
lysed Toxoplasma's tachyzoites after centrifugation at 13,000 x G,
Immunity to Toxoplasma occurs as both cell-mediated and humoral
responses. Humoral antibody consists mainly IgM and IgG. However, the
cel 1-mediated immune response is of greater importance than the humoral
response to T. gondii in mediation of effective immunity against Toxoplasma
(Frenkel, 1967). Macrophage involvement in toxoplasmosis has been shown by
the fact that delayed hypersensitivity can be elicited in vitro by the
macrophage migration inhibition and also in vivo (Krahenbuhl et al., 1971).
Influence of Toxoplasmosis on
Other Microbial Infections
Toxoplasmosis in mice has been reported to have protected these
animals against a variety of unrelated organisms and diseases (Remington
et al., 1969). The Toxoplasma-infected mice have been demonstrated to be
resistant to a variety of phylogenetically unrelated organisms such as Mengo
virus and Cryptococcus nebformans (Remington and Merigan, 1978), Listeria
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monocytogenes and Salmonellae typhimurium (Remington and Ruskin, 1968), and
Schistosoma mansoni (Mahmoud et al., 1976).
Toxoplasmosis and Tumor Suppression
Remington and others (1971) reported that intracellular protozoa,
including Toxoplasma conferred resistance to murine tumors, spontaneous
mammary carcinoma in C3H/He mice, to spontaneous leukemia in AKR mice, to
leukemia induced in Swiss-Webster mice by Friend leukemia virus, and to
transplantable tumor sarcoma 180 and leukemia 1210. It was recently de¬
monstrated in our laboratory by Seele (1979) that C57BL/6j mice latently
infected with C-56 X- gondii were resistant to metastatic B16 melanoma tumor.
The assumption in all cases was that the cells which mediated this protec¬
tion were the macrophages which had become activated as a result of the
parasitic infection. This assumption has not been conclusively demonstrat¬
ed.
Other Protozoans and Chemical
Irritants in Tumor Regression
A broad spectrum of organisms besides T. gondii have been demonstrat¬
ed to enhance tumor regression in mice. For example, the growth of allo¬
geneic and syngeneic tumors have been shown to be markedly inhibited in rats
and mice injected with Nippostrongylus brasiliensis. Schistosoma mansoni,
Besnoitia jellisoni (Remington et al., 1971). Many bacteria also demon¬
strated this ability. For example, tumor resistance has been observed in
mice infected with live Bacillus Calmette-Guerin (BCG), killed or cell wall
fraction of BCG COld et al,, 1959; Weiss et al., 1961) and in live or killed
vaccine of Corynebacterium parvum (Woodruff et al., 1966: Currie et al., 1970).
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The use of chemicals to enhance tumor suppression in the mice has
also been reported by many authors. Hibbs and others (1971) reported that
injection of complete Freund's adjuvant resulted in regression of both
allogeneic and syngeneic tumor growth. Levy and others (1969) reported
the use of irritants like poly I: poly C, endotoxin or peptone in regres¬
sion of tumor growth. Again the conclusion was that macrophages of these
mice were the major effector cells in the inhibition and destruction of
the tumor cells both in vivo and in vitro.
Mechanism of Macrophage Activation
and Immunity
Reikvam (1976) observed a profound proliferation of macrophages
and lymphocytes in mice infected with X* gondii. Remington and his asso¬
ciates (1972), using labelled uridine, observed an enhanced killing of
Toxoplasma by activated macrophages of T. gondii-infected mice. The macro¬
phages were activated approximately 14 days post-infection of Toxoplasma.
Jones (1974) suggested a mechanism by which host macrophages inhibit Toxo¬
plasma proliferation in vitro. He suggested that, when immune lymphocytes
come in contact with Toxoplasma antigen, they release a lymphokine wHIch is
known as Toxoplasma initiating factor (Toxo.IF), This interacts with a
gylcoprotein fixed on the surface of the macrophage, resulting in macro¬
phages which can inhibit Toxoplasma proliferation. These macrophages are
called activated macrophages. Hibbs and others (1972) demonstrated that
these activated macrophages obtained from suitably immunized mice are
responsible for the protection of the host mice aginst tumor or against
proliferation of certain microbes. These macrophages, on coming in contact
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with specific antigens, undergo proliferation and transformation which
renders them cytostatic or cytotoxic. Phagocytosis vms not observed in
the procedure; therefore, Krahenbuhl and Lambert (1975) hypothesized that
cell to cell contact between the macrophages (effectors) and the target
cells is necessary for cytostasis. On the contrary, Calderon and others
(1974) suggested that macrophages effect cytostasis through secretion of
arginase; a soluble factor or enzyme. This enzyme is secreted into the
cytoplasm of the target cells and is involved in breaking down of the cell
(Hibbs, 1974).
B16 Melanoma
The B16 melanoma originated spontaneously in a C57B1 mouse at
Jackson laboratory. Bar Harbor, Maine in 1954. It contains a high molecular
weight RNA of 70 S size associated with a reverse transcriptase.
When B16 melanoma cells are injected intravenously into C57B1 mice,
secondary tumors develop in distant organs, usually the lungs, where they
appear as discrete pigmented tumor nodules against the transparent lung
tissue. This system is suggested as a excellent system for quantitating
tumor growth experiments (Fidler, 1970). On injection melanoma, as a rule,
invades the regional lymph nodes first, resulting in a widespread visceral
metastasis through both the lymphatic and hematogeneous routes CHarris et
al., 1976).
Borland (1965) defined metastasis as the transfer of disease from
one organ or part to another not directly connected with it. The develop¬
ment of metastasis is dependent on an interplay between host factors and
intrinsic characteristics of malignant tumor cells. The process is highly
selective and the metastatic lesion represents the end point of many de¬
structive events that only a few cells can survive (Fidler, 1975).
In vivo, cancer metastasis involves five steps (Fidler, 1970, 1973a,
1975; Fidler and Kripke, 1977; del Regato, 1977). First is the local in¬
vasion of cells from the primary tumor into surrounding tissue and pene¬
tration of blood and/or lymph vessels of the host, followed by the release
of tumor cell emboli into the circulation. During circulatory transport,
tumor cells can undergo a variety of interactions, including aggregation
with other tumor cells (Nicholson and Winkehake 1975; Nicholson and Burnson,
1977), platelets (Basic et al, 1973), lymphocytes and other host cells
(Fidler, 1974). It has been demonstrated experimentally that larger emboli
are more effective in implantation and in survival to form gross tumor
colonies after intravenous injection CFidler, 1973b). Moreover, these em¬
boli are easily arrested in small vascular channels of distant organs
where the tumor cells invade the wall of the arresting vessel, followed by
infiltration into adjacent tissue, multiplication, growth of vascularized
stroma into the new tumor and finally secondary tumor growth, resulting from
the final development of the arrested tumor emboli.
Clinical and experimental observations show a predilection of cer¬
tain neoplasms for growth in specific organs; thus suggesting that the
pattern of metastasis is not random but rather that it reflects properties
of the circulating malignant cells, host capillary endothelium, and organ
environment (Fidler and Nicolson, 1976).
Three hypotheses have been advanced to explain this destructive
pattern of distribution of metastasis. First, Erwing C1928) suggested that
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metastasis is influenced by purely "mechanical factors," such as anatomic
and hemodynamic factors in the vasculature. In contrast, Paget (1889)
suggested the seed and soil hypothesis which states that the micro-environ¬
ment of one organ may favor the arrest and subsequent growth of tumor em¬
boli, while the macro-environment of another organ may not. Finally,
using Cloudman melanoma and miirine fibrosarcoma, Kinsey (1960) and Sugar-
baker et al. (1971), respectively, demonstrated tumor cells homing to and
growing in specific organs as a result of their unique genetic properties.
To explain the reason why cancer cells metastasize, Fidler and
Kripke (1977) demonstrated that malignant tumors are heterogeneous; that is,
there are variant cells within the malignant tumors with unique ability to
metastasize. They also showed that the majority of B16 melanoma cells
injected into syngeneic C57B1 mice by any route died very rapidly in the
circulation and only about 0.1 percent survived and metastasized. They
further demonstrated that simultaneous in vivo passage, extraction and
tissue cultivation of malignant B16 tumor cells resulted in increased
ability of the subsequent tumor variants to implant, survive and form lung
tumors. For example, BIB-F^q, obtained after ten in vivo passages and
simultaneous tissue cultivations, formed significantly more gross lung
tumors per input of cells than did BIG-F^, the parent cell, after an intra¬





The C-56 strain of Toxoplasma gondii was obtained from Dr. Jack
Remington of Stanford University, Palo Alto, California and used for all
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experiments. It was maintained by Injecting Swiss-Webster mice with 10
tachyzoites of the parasite intraperltoneally and with 0.1 ml of cortisone
acetate intramuscularly. The mice were sacrificed nine days post-infection
and peritoneal exudates obtained from them were centrifuged. The sedimented
tachyzoites were washed, counted In a hemacytometer and resuspended in PBS.
The Mice
C57Bl/6j male mice, eight weeks old, were purchased from Cumberland
View Farms, Clinton, Tennessee. These were used In all experiments In¬
volving B16 melanoma cells.
Swiss-Webster CSW) female retire breeder mice,obtained from the
Center for Disease Control, Atlanta, Georgia, were used In the cultivation
and propagation of the C-56 strain of Toxoplasma gondii.
The Tumor Cells
The F-j subline of B16 melanoma cells was obtained from Dr. I. J.
Fidler of Fredrick Cancer Research Center, Fredrick, Maryland, The cells
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were maintained in C57BL/6j mice by injecting these mice with 10^ cells of
the B16 melanoma intraperitoneally. The mice were sacrificed three weeks
post-injection and the friable masses of tumor cells were collected from
the peritoneal cavity, passed through a 50 mesh stainless steel screen,
washed and resuspended in RPMI 1640 medium.
Cortisone Acetate
Cortisone acetate (cortone-acetate) in a saline suspension contain¬
ing 50 mg ml~^ of cortisone acetate was obtained from Merck, Sharp and
Dohme, Inc., West Point, Pennsylvania.
Protein Assay
Protein assays were performed with the aid of protein assay kits
obtained from Bio-Rad Laboratories, Richmond, California.
Immunoelectrophbresis
Hyland immunoelectrophoresis supply packages were obtained from
Hyland Division Travenol Laboratories, Inc., Costa Mesa, California.
Anti-Serum
Human Anti-ToxOplasma serum was obtained from Dr. Alexander Sulzer
of the Center for Disease Control, Atlanta, Georgia
Freund's incomplete Adjuvant (FIA)
Freund's incomplete adjuvant was obtained from Grand Island Biological
Company, Grand Island, New York.
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Effect of Cortisone Acetate on Pro-
liferation of T^, gondii .C-56
5
Ten Swiss-Webster mice were injected intraperitoneally with 10
tachyzoites of gohdii C-56 and simultaneously injected with 0,2 ml of
cortisone acetate into their hind leg muscles. The mice were fed with
chlor-tetracycline in their drinking water at a concentration of 100 mg
ml“^ of water (Remington et al., 1969). The control for this experiment
consisted of one group of 10 mice injected with Toxoplasma tachyzoites only
and no cortisone; another group of mice injected with cortisone, fed with
chi or-tetracycline but not injected with X- gondii; and, finally a third
group injected with Toxoplasma and cortisone but not fed with chlor-tetra-
cycline.
Nine days post-infection, four mice from each group were sacrificed
and peritoneal exudate was aspirated asceptically into separate test tubes
of 5 ml buffered saline solution containing 10 units of heparin ml'^ The
tachyzoites were washed twice by centirugation in PBS at 1000 x G for 20
minutes each and then counted in a hemacytometer.
Nineteen days post-infection, another four mice from each group
were sacrificed and tachyzoites obtained were washed and counted as described
above. The remaining mice (two mice per group) were left to die in order to
determine the timaaf death.
Collection and Fractionation of C-56
Toxoplasma Tachyzoites
5
Forty Swiss-Webster mice were injected with 10 tachyzoites intra¬
peritoneally, The mice were iramunosuppressed with cortisone-acetate and
fed with chlor-tetracycline in their drinking water as previously described.
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Nine days post-infection, exudates were aspirated asceptically from their
peritoneal cavity into a 50 cc centrifuge tube containing heparinized
buffered saline. The tube was then incubated for 24 hours at 37°C to allow
cells to adhere to the tube. The exudate was then carefully decanted into
another clean 50 cc tube. Free tachyzoites were released by forcing the
exudates through a 27 guage needle. The tachyzoites were then sedimented
by centrifugation at 1000 x G for 20 minutes. The supernatant was collect¬
ed into 15 cc tubes and labelled "Toxo-supernantant antigen." The pellet
was sedimented, washed twice in buffered saline by centrifugation at 1000
Q
X G and counted in a hemacytometer C4.5 x 10 cells).
Preparation of Antigen
The method of fractionation used was a modification of that describ¬
ed by Jacobs et al. (1959) and Lai et al. (1975). The sample containing
9 8
4.5 X 10 parasites was resuspenfed in PBS to contain 1 x 10 parasites
ml~^. This v/as vortexed gently and divided equally into four 15 cc centri¬
fuge tubes so that each tube contained 8 ml of suspension. The organisms
in one centrifuge tube were used in the establishment of latent infection,
while organisms in the other three tubes were either lysed or treated with
formalin.
Formalinization
Two ml of 0.5% formalin were added to one tube to give a final con¬
centration of 0.1% formalin. The preparation was then refrigerated at 4°C
for 48 hours; after which, the tachyzoites were sedimented and washed twice
in PBS by centrifugation at 1000 x G, The tachyzoites were then resuspended
in 8 ml of PBS.
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Lysis
Another tube was selected and its tachyzoite content was washed
and resuspended in 8 ml of distilled water; then refrigerated at 4C for
24 hours. After refrigeration, the parasites were further lysed by five
cycles of freeze-thawing. Following lysis, the cytosol was centrifuged at
14,000 X G to separate the cytosol-supernatant from the cell membrane
material. The cytosol-supernatant was collected into a clean dry 15 cc
centrifuge tube and called "cytosol-supernatant antigen." The sediment
was washed in PBS and resuspended in 8 ml of PBS and labelled "cell membrane
antigen." The procedure for antigen preparation is summarized in Figure 1.
Establishment of Latent
Toxoplasma Infection
Six C57BL/6j mice were infected with 10^ tachyzoites of X* gondii
C-56. Three days post-infection, sulfadiazine solution was substituted as
drinking water for the mice (Remington et al., 1969). The sulfadiazine
solution was prepared by dissolving 500 mg of sulfadiazine and 46 mg of
sodium bicarbonate (NaHCO^) in 1000 ml of distilled water. This drug was
administered to the mice for theee weeks and then terminated. The control
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for this experiment was a group of four mice infected with 10 cells of
the parasite but not treated with sulfadiazine.
Immunoelectrophoresis
This experiment was done to test the reaction of the Toxoplasma
antigens with human Toxoplasma antiserum. The protein content of each
fraction was estimated using the Bio-Rad protein concentration assay
technique (Bio-Rad Laboratories, Richmond^ Ca.). The concentrations




































obtained are shown in Table 1.
TABLE 1
PROTEIN CONCENTRATION OF FRACTIONS
OF C-56 TOXOPLASMA GONDII
Fractions of T. gondii Protein Concentration
(mg ml" )
Cell Membrane Antigen 8.3
Cytosol Supernatant Antigen 10.2
Lysed Toxo Antigen 9.8
Toxo Supernatant Antigen, 1st wash 11.2
The immunoelectrophoresis v/as performed using the immunoelectro-
phoresis kit obtained from Hyland Division Travenol Laboratories, Costa
Mesa, CA. A pre-punched agar gel-plate was selected and the troughs were
filled with human Toxoplasma antiserum, while the wells were filled with
their respective designated fractions. Current v/as then applied for 35
minutes at 30 mA; after which, the plate was incubated in a moist chamber
for 18 hours at room temperature.
Immunization of Mice with Toxoplasma Antigen
The method of immunization used was described previously by
Krahenbuhl et al. (1972). Each antigen was emulsified with Freund's incom¬
plete adjuvant (FIA) in a ratio 1:1. Eight groups of seven mice were used.
Mice from each group received 0.2 ml of their designated antigen, subcutaneous¬
ly and intraperitoneally. Three weeks after immunization, three mice from
each group were separated from the group and given an intraperiotoneal
20
challenge dose of 10^ T_. gondii in 0.2 ml of PBS.
Intravenous Innoculation of B16
Melanoma Tumor Cells
The method described by Fidler {1973a) was used in this experiment.
B16 melanoma (F^ subline), originally obtained from Fredrick Cancer Research
Center and now maintained in our laboratory, was used as tumor source. The
viability and number of the tumor cells were estimated by staining with
Trypan blue and counted in. a hemacytometer. Four mice were taken from
each of the immunized groups and injected intravenously with 0,2 ml of sus-
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pension containing 5 x 10 B16 melanoma tumor cells. For the control of
this experiment, three groups of four mice were used. One group of mice re¬
ceived PBS and FIA only, another group consisted of mice latently infected
with Toxoplasma; and the third group was normal, unimmunized mice. Twenty-
one days later, all mice were sacrificed and the occurrence of metastasis
was observed by quantitating the number of nodules observed on the lungs of
the mice. The criterion for determining suppression was the number of
nodules observed in the lungs of immunized groups of mice compared with
the number observed in the lungs of the control group of mice.
CHAPTER IV
EXPERIMENTAL RESULTS
The Effect of Cortisone Acetate on
Proliferation of Toxoplasma
gondii C^^
The effect of cortisone acetate on proliferation of Toxoplasma
gondii C-56 is shown in Table 2. The table demonstrates that, when mice
were injected with only the Toxoplasma, clinical symptoms and peritoneal
exudates could be obtained on the 19th day post-infection, but not on the
ninth day. Whereas, when the mice were immunosuppressed with cortisone,
these symptoms appeared as early as the ninth day, with death occurring any¬
time thereafter. The table also demonstrates that more tachyzoites were ob¬
tained from mice that were not treated with cortisone. This can probably
be attributed to the fact that these mice lived for 19 days before succumb¬
ing; therefore, allowing more time for the parasites to proliferate as op¬
posed to mice treated with cortisone.
ImmunoelectrOphoresis
The parameter used for determining reaction of the fractions with
the human Toxoplasma antiserum was the appearance of a white precipitate of
the complex formed by the Toxoplasma antigen and the human Toxoplasma anti¬
serum. The results (Figure 2 ) show that all fractions of the parasite formed
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a white precipitate with the human Toxoplasma antiserum. The soluble anti¬
gen demonstrated some mobility, while the insoluble antigen remained at
the point of origin.
TABLE 2
THE EFFECT OF CORTISONE ACETATE ON PROLIFERATION
OF C-56 TOXOPLASMA GONDII








3 X 10® Dead
Toxoplasma Only;
No Cortisone
0 5.2 X 10®
Cortisone; Tetracycline;
No Toxoplasma
No Toxoplasma No Toxoplasma
Toxoplasma; Cortisone;
No Tetracycline
3.2 X 10® Dead
1 5
All mice were injected with 0.2 ml of a suspension containing 10
tachyzoites of X* gondii.
2
Four of eight mice were sacrificed on the ninth day.
3
Four of eight mice were sacrificed on the nineteenth day.
Fig. 2. Precipitin reaction of X- gondii fractions with
human anti- Toxoplasma serum.
a. Supernatant of Toxoplasma-induced
peritoneal exudate.
b. Suspension of parasites washed with
PBS and lysed in distilled water,
followed by five cycles of freeze¬
thawing.
c. Supernatant of lysed parasites.




EFFECT OF IMMUNIZATION OF MICE WITH VARIOUS
FRACTIONS OF C-56 TOXOPLASMA GONDII
Experimental Group^ of
Mice Treated With Antigen
Number of Mice Surviving
After Challehgel
5 Weeks 6 Weeks
Toxoplasma Supernatant Antigen 3 1
Formalin Killed Toxo Antigen 3 3
Lysed Toxo Antigen 3 3
Cytosol Supernatant Antigen 3 0
Cell Membrane Antigen 3 2
PBS + FIA^ 0 0
2
Normal Mice 0 0
Latent T. gondii Infection 3 3
^Each group consisted of three mice; each mouse received
dose of 10° tachyzoites of T. gondii C-56,
a challenge
2
The control mice all died within three weeks.
TABLE 4
METASTASIS OF B16 MELANOMA IN C57BL/6J MICE
SENSITIZED WITH C-56 TOXOPLASMA
GONDII FRACTIONS
Experimental Groups of Mice ,






Toxoplasma Supernatant 13.0 64
Formalin Killed Toxo 5.0 86
Lysed Toxo Antigen 6.0 83
Cytosol Supernatant 16.0 56
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TABLE 4—M^ontinued
Cell Membrane Antigen 5.0 86
FIA + PBS 35.0 3
Normal Mice 36.0 0
Latent Toxo Infection 0.75 98
^Each group consisted of four mice.
2 4
All mice were injected with 5 x 10 B16 melanoma cells intravenously.
3
All mice were sacrificed 21 days post-tumor injection.
Results of Challenge
Ordinarily, when normal C57BL/6J mice are infected with a lethal
dose of T. gondii C-56, they die within 19-21 days. The result of this
experiment (Table 3), however, demonstrated that the vaccines prepared from
the parasite as well as the killed parasite extended survival time of the
mice five to six weeks or more. It is also seen from the Table that im¬
munized mice showed varying degrees of resistance to challenge. Those re¬
ceiving formalin-killed or lysed Toxoplasma antigen survived as well as con¬
trol mice bearing latent infection with live parasites. Sixty-seven percent
of mice receiving cell membrane survived for six weeks; whereas, only 30%
of mice immunized with supernatant antigen were alive at six weeks. In con¬
trols of these experiments, non-immunized mice survived a maximum of three
weeks after challenge.
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Metastasis of B16 Melanoma CFj Subline) in
C57BL/6J Mice Sensitized with Toxoplasma
gondii C-56 Fractions
The results obtained for the metastasis of B16 melanoma in C57BL/6J
mice sensitized with fractions of Toxoplasma gondii C-56 are shown in Table
4. These results demonstrate that all the fractions were capable of stimu¬
lating inhibition of tumor metastasis but the formal in-killed Toxoplasma
antigen, lysed Toxoplasma antigen and cell membrane antigen appeared to have
capabilities that most closely approaches that of the latent infection.
CHAPTER V
DISCUSSION AND CONCLUSIONS
Toxoplasma gondii C-56 is an avirulent strain and, as such, Swiss-
Webster mice are able to endure the parasite for more than two weeks before
succumbing to infections. However, the use of cortisone acetate, an immuno¬
suppressive drug, in the cultivation of this parasite demonstrated that the
drug decreased the time to death of the mice. By suppressing the immune
response of the mice, the tachyzoites of T, gondii C-56 were able to under¬
go rapid and unrestricted proliferation, and could therefore be obtained in
the mouse exudate three to five days after infection as opposed to three
weeks without the use of cortisone.
The mechanism of this suppression is similar to that occurring in
irradiated, thymectomized or splenectomized mice in which the immune re¬
sponse of the mice was eliminated or suppressed, allowing free growth of
X.V gondii C-Frenkel et al,, 1966), The ability of fractions to protect
hosts against T. gondii infection was also demonstrated in the study. The
longest lasting protection was demonstrated in mice treated with formalin-
killed antigen and lysed T. gondii antigen. Iiimunoelectrophoresis of the
fractions also demonstrated that the fractions contain antigen homologous to
the human Toxoplasma antiserum, since all fractions reacted with the human
antiserum. The results also demonstrated a significant resistance to B16
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melanoma CF^ subline) proliferation in the mice immunized with fractions
of T. gondii C-56.
The results obtained in this study correlate with the use of
killed vaccines in immunization against an intracellular parasite. Toxo¬
plasma gondii) reported by Krahenbuhl et al., 1972. The results also corre¬
late with the regression of B16 melanoma tumor in C57BL/6J mice latently
infected with T. gondii C-56 reported by P. Seele (1979). These observa¬
tions also correlate with the results obtained by the use of other thera¬
peutic anti-tumor agents against tumor proliferation in mice, e.g. Coryne-
bacterium parvum as an anti-tumor agent against mastocytoma P815 (Scott,
1974); effects of BCG on transplanted tumors (Old et al., 1959); effects of
killed vaccine of BCG on leukemia (Davignon et al., 1970); adjuvant induced
resistance to tumor development in mice (Hibbs et al., 1971). In all these
reports, the resistance was attributed to the non-specific activation of
the macrophages of the experimental animals, resulting in an increased
cytotoxic capability of the macrophages. Hibbs (1974) noted that lysosomal
enzymes from the activated macrophages are secreted into the cytoplasm of
the tumor cells, thus causing tumor lysis and destruction. Similarly, the
results obtained in this study could be due to the persistence of the
Toxoplasma antigen in the C57BL/6J mice, which non-speficially activated the
macrophages with the ability to inhibit the proliferation of the B16 melanoma.
In conclusion, this study provided evidence that protection of
mice against re-infection by T. gondii C-56 or against proliferation of
melanoma B16, a metastatic tumor, did not require the use of live or whole
parasites. It demonstrated that fractions obtained from the~T. gondii v;ere
equally effective.
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There is growing interest in devising various methods of stimulat¬
ing host resistance to growth of cancer metastasis for human use. Scientif¬
ic investigators from many geographical locations are now employing BCG im¬
munotherapy in stimulating resistance to neoplasia in man. Since Toxoplasma
is a common parasite in man and since the organism remains in the tissue of
man, probably for life, it would be of interest, as suggested by Hibbs et
al. (1971) to know what effects, if any, infection with this parasite might
have on development of tumors in humans. Furthermore, an epidemiological
study correlating natural infection with Toxoplasma and subsequent tumor
development in humans would be worthwhile. Methods of fractionation and
purifying the parasite should be advanced and further study of its effect on
neoplasia should be extended to humans.
CHAPTER VI
SUMMARY
1. By innumosuppressing Toxoplasma-infected mice with
cortisone acetate, the time to death period of the
mice was reduced. This is probably why less number
of tachyzoites were obtained from these sick mice
compared to the number obtained from the sick mice
that did not receive cortisone acetate.
2. All fractions formed the white precipitate with
the human Toxoplasma antiserum; thus indicating
that the fractions contained antigen homologous to
the human antiserum.
3. All fractions of Toxoplasma gondii provided some pro
tection to the mice against challenge with a lethal
dose of Toxoplasma.
4. All fractions demonstrated some capability of in¬
hibiting metastasis of B16 melanoma tumor.
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